belinostat

Known as: 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)- 
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
PURPOSE Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no… (More)
Is this relevant?
2014
2014
Belinostat [Beleodaq® (US)], a small-molecule hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE We aimed to compare the potential for inducing HIV production and the effect on T-cell activation of potent HDAC… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC). In this study of patients with unresectable… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Thymic epithelial tumors are rare malignancies, and there is no standard treatment for patients with advanced disease in… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
2007
2007
Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new… (More)
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Recently, the role of transcriptional repression through epigenetic modulation in carcinogenesis has been clinically validated… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?